Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,889,079
  • Shares Outstanding, K 275,778
  • Annual Sales, $ 198,960 K
  • Annual Income, $ -11,940 K
  • EBIT $ 54 M
  • EBITDA $ 62 M
  • 60-Month Beta 1.28
  • Price/Sales 8.73
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 162.55% ( +85.06%)
  • Historical Volatility 42.45%
  • IV Percentile 99%
  • IV Rank 69.73%
  • IV High 229.09% on 04/30/24
  • IV Low 9.30% on 10/22/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 6,531
  • Volume Avg (30-Day) 2,607
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 96,997
  • Open Int (30-Day) 90,023

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.03
  • Low Estimate 0.03
  • Prior Year 0.01
  • Growth Rate Est. (year over year) +200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.81 +17.90%
on 12/17/24
7.07 -3.11%
on 12/20/24
-0.03 (-0.44%)
since 11/20/24
3-Month
5.81 +17.90%
on 12/17/24
7.63 -10.22%
on 11/06/24
+0.25 (+3.79%)
since 09/20/24
52-Week
3.17 +116.09%
on 02/05/24
7.63 -10.22%
on 11/06/24
+3.51 (+105.40%)
since 12/20/23

Most Recent Stories

More News
MannKind Corporation Reduces Debt by $194 Million and Strengthens Cash Position to Over $180 Million

MannKind Corporation reduces debt by $194 million and increases cash position to over $180 million through note exchanges.Quiver AI SummaryMannKind Corporation has announced a significant reduction in...

MNKD : 6.85 (+8.73%)
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

MNKD : 6.85 (+8.73%)
MannKind Corporation to Discuss Afrezza Diabetes Study Results and Upcoming FDA Meeting Plans

MannKind plans FDA meeting for potential Afrezza supplemental application after positive Phase 3 diabetes study results in youth.Quiver AI SummaryMannKind Corporation announced today that it plans to meet...

MNKD : 6.85 (+8.73%)
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MNKD : 6.85 (+8.73%)
MannKind Corporation and Cipla Ltd. Announce CDSCO Approval for Afrezza Inhalation Powder in India

MannKind's Afrezza inhaled insulin approved in India for diabetes treatment, expected to ship by end of 2025.Quiver AI SummaryMannKind Corporation has announced that India's Central Drugs Standard Control...

MNKD : 6.85 (+8.73%)
MannKind Stock Gains After India Approves Inhaled Insulin: Retail Excitement Builds

This milestone adds India to the list of countries where Afrezza is approved, joining the United States and Brazil.

MNKD : 6.85 (+8.73%)
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

MNKD : 6.85 (+8.73%)
Insider Sale: Director at $MNKD (MNKD) Sells 67,536 Shares

Steven B. Binder, a director at $MNKD ($MNKD), sold 67,536 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.9% of their shares....

MNKD : 6.85 (+8.73%)
MannKind (MNKD) Q3 2024 Earnings Call Transcript

MNKD earnings call for the period ending September 30, 2024.

MNKD : 6.85 (+8.73%)
MannKind: Q3 Earnings Snapshot

MannKind: Q3 Earnings Snapshot

MNKD : 6.85 (+8.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

3rd Resistance Point 7.95
2nd Resistance Point 7.51
1st Resistance Point 7.18
Last Price 6.85
1st Support Level 6.41
2nd Support Level 5.97
3rd Support Level 5.64

See More

52-Week High 7.63
Last Price 6.85
Fibonacci 61.8% 5.93
Fibonacci 50% 5.40
Fibonacci 38.2% 4.87
52-Week Low 3.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar